HoloMonitor M4

Coming Events

Current methods force scientists to study life’s fundamental building block when it is dying. PHI’s non-destructive Holo­Monitor technology allows the long-term behavior of living cells to be observed and quantified without toxic stains.

PHI leads the ground-breaking development of time-lapse cyto­metry instru­men­ta­tion and software. With the first Holo­Monitor instru­ment introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circum­vent the drawbacks of traditional methods requiring toxic stains.

Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to pro­moting the science and practice of time-lapse cyto­metry, PHI is actively expanding its customer base and scientific col­lab­ora­tions in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

PHI was founded by its current manage­ment with the support of Lund University and Sweden’s Innovation Agency, VINNOVA. Since early 2014 the PHI stock is publicly traded on AktieTorget.